Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Experimental Medicine in Psychiatry.

AIMday banner and delegate registration desk

The University of Oxford is hosting an AIMday in Experimental Medicine in Psychiatry industry event on Wednesday 7 July 2021 (virtual event).

The AIMday format allows industry to propose challenges for one-hour roundtable discussions with groups of relevant academics and clinicians from Oxford. For academics, this is a great chance to see how your research can be applied in industry and to meet potential future collaborators. View the list of challenges put forward by industry.

Participating companies include: Lundbeck, Compass Pathways, P1vital, Circadian Therapeutics, Zogenix, Cyclica, Precision Life, Beckley Psytech, BrainBerry, Brain Cures, BrainPatch, Braxia Scientific, Psious & Ranvier Health.

The agenda also includes some exciting talks from Professor Wayne Drevets (Johnson & Johnson), Professor Catherine Harmer (University of Oxford) & Dr Adam Babbs (MRC).

Registration for Oxford researchers is now open and will close on Friday 25 June. Advance registration is essential.

Read more about the AIMday in Experimental Medicine in Psychiatry and register to attend

For more details, please contact Amira Burshan, Business Engagement Facilitator, Business Partnerships Office.

Similar stories

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

Immunology and AI drug discovery partnership agreed with Sensyne Health

The University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine’s Respiratory Medicine Unit.

Oxford overseas research facility expands to include diagnostics and genetics testing centre

The Oxford-Suzhou Centre for Advanced Research, known as OSCAR, has marked another significant milestone with the launch of OSCAR-Prenetics Innovation and Technology Centre for Advanced Molecular Diagnostics (the OSCAR-Prenetics ITC).

Oxford joins forces with 11 universities to launch social impact investment fund

The University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.

Innovation award for Professor Anindita Roy to develop new treatments for childhood cancer

Associate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of £4.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children’s and young people’s cancers, with the hope of finding new ways to prevent and treat these complex cancers.

Association of Physicians of Great Britain and Ireland Annual Meeting opens to wider medical community for first time in over a century

Established in 1907, the Association of Physicians of Great Britain and Ireland (AoPGBI) has traditionally only invited the highest-profile doctors and researchers to its annual meeting. Now, they have made the landmark decision to open their (virtual) doors to the wider medical community, primarily to clinicians, early career researchers, discovery scientists and industry affiliates.